Market Access A dynamic moment for pharma pricing: Insights from PPIC At PPIC in Basel, pharma pricing experts discussed how policy changes and AI advances are altering the dynamics of pharmaceutical pricing and access.
News In brief SOTU remarks, Trump asks Congress to "codify" MFN In a speech at least nominally focused on the economy and affordability, President Trump put surprisingly little emphasis on his drug pricing efforts.
Market Access Policy in Focus: Unpacking GLOBE, GUARD, and TrumpRx with Al... Unpack the impact of Most-Favoured Nations in GLOBE and GUARD pricing models, and TrumpRx, with Alice Valder Curran's clear policy overview.
Market Access Policy in focus: Trump’s Most Favoured Nations drug pricing ... Alice Valder Curran, a partner at Hogan Lovells, provides an update on what's happening right now with Most Favoured Nations drug pricing.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.